Abstract
Δ3,2-Hydroxybakuchiol is isolated from Psoralea corylifolia (L.), which has therapeutic applications in traditional Chinese medicine. Our previous studies have showed that Δ3,2-hydroxybakuchiol inhibited the decreased activity of reserpinized mice, suggestive of its antidepressive potential. In this study, we explored the antidepressant profile of Δ3,2-hydroxybakuchiol in various rodent models and its possible monoamine-modulating mechanism. Δ3,2-Hydroxybakuchiol significantly reduced immobility time of mice in forced swim test and tail suspension test. Δ3,2-Hydroxybakuchiol also significantly increased sucrose consumption in chronic unpredictable mild stress (CUMS) rat model. Furthermore, isotope uptake study showed that Δ3,2-hydroxybakuchiol inhibited the activity of human dopamine transporter (DAT) and norepinephrine transporter (NET) in transporter-overexpressing pheochromocytoma (PC12) cells with IC50 values similar to the potency of bupropion. Microdialysis showed that Δ3,2-hydroxybakuchiol increased dopamine and norepinephrine concentration in rat striatum. In summary, Δ3,2-hydroxybakuchiol exerts antidepressant effects on various types of depression models through a possible mechanism of monoamine transporter inhibition.
References
Feb 15, 1978·European Journal of Pharmacology·R D PorsoltM Jalfre
Jan 1, 1981·Neuroscience and Biobehavioral Reviews·R J KatzB J Carroll
Jul 5, 2001·Physiology & Behavior·R J BlanchardD C Blanchard
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Abdalla Salem Elhwuegi
Aug 25, 2004·Behavioural Brain Research·Stéphanie PothionCatherine Belzung
Dec 21, 2004·Psychopharmacology·Benoit Petit-DemouliereMichel Bourin
May 14, 2005·Neuroscience and Biobehavioral Reviews·John F CryanAnnick Vassout
May 17, 2005·Neuroscience and Biobehavioral Reviews·Alan Frazer, David A Morilak
Sep 3, 2005·Nature Reviews. Drug Discovery·John F Cryan, Andrew Holmes
Feb 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Magdalena N JayatissaOve Wiborg
Oct 18, 2007·Expert Review of Neurotherapeutics·Chi-Un PaeChul Lee
Mar 11, 2008·Biochemical Pharmacology·Gang ZhaoLi-He Guo
Sep 20, 2008·The British Journal of Nutrition·Sun-Hye LimSuna Kim
Mar 27, 2009·Cellular and Molecular Life Sciences : CMLS·G ZhaoL-H Guo
Jul 7, 2009·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·D XinX-M Gao
Jan 25, 2011·Expert Opinion on Therapeutic Targets·Kanwaljit ChopraAnurag Kuhad
Apr 23, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michel Hamon, Pierre Blier
Jun 27, 2013·Cell and Tissue Research·Ove Wiborg
Aug 15, 2013·Cell and Tissue Research·Vincenzo MicaleAlexandra Sulcova
Sep 3, 2013·Expert Opinion on Drug Discovery·Kalyan ImmadisettyJeffry D Madura
Sep 24, 2013·Advances in Pharmacology·Julie G HenslerWouter Koek
Nov 16, 2013·Toxicology and Applied Pharmacology·Haoping MaoXiu Mei Gao
Feb 27, 2015·Reviews in the Neurosciences·Marzieh Sarbandi FarahaniRoja Rahimi
Jul 18, 2015·The American Journal of Psychiatry·Tsafrir GreenbergMary L Phillips
Jul 18, 2015·PloS One·Lingling DingNing Wu
Aug 6, 2017·Sleep Medicine Clinics·Régis LopezYves Dauvilliers